SCHEMBL7044628

SCHEMBL7044628

COC(=O)c1cccc2ncc(-c3ccc(Br)cc3)nc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.60
SLC6A3 Q01959 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
KMT2A Q03164 5/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
ATM Q13315 1/20 0.47
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
NPC1 O15118 3/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TP53 P04637 2/20 0.42
PLA2G2A P14555 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ESR1 P03372 1/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 1/20 0.40
NFKB1 P19838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779160 0.88 PARP1 (0.60) PARP1SLC6A3PARP2KMT2AKDM4E
SCHEMBL7039533 0.84 PARP1 (0.60) PARP1PARP2ALDH1A1
SCHEMBL7042977 0.83 PARP1 (0.78) PARP1PARP2KMT2A
SCHEMBL7044629 0.78 PARP1 (0.46) PARP1SLC6A3KMT2AKDM4EGAA
SCHEMBL4779209 0.78 PARP1 (0.71) PARP1SLC6A3PARP2KMT2AKDM4E
SCHEMBL21638317 0.77 KDM4E (0.55) PARP1KMT2AKDM4EGAAATM
SCHEMBL7045177 0.75 PARP1 (1.00) PARP1PARP2KMT2AMAPTMEN1
SCHEMBL71209 0.74 KDM4E (0.74) KMT2AKDM4EGAAATMMAPT
SCHEMBL31353202 0.73 PARP1 (0.59) PARP1PARP2KMT2AMEN1NPC1
SCHEMBL1034874 0.73 PARP1 (0.62) PARP1PARP2KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003007959-A1 QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-01-30 WO disclosed